SUMMARY Assessment of vascularity and blood-tissue barrier was performed by sequential scintigraphy in 43 patients with brain tumours. The blood-tumour barrier was evaluated by use of 99mTc-pertechne:tate, and vascularity using 99"mTc-labelled red blood cells. Penetration of pharmaceuticals into the tissue of brain tumours has been a subject of interest to a number of investigators, and a variety of directions were emphasised (Matthews and Molinaro, 1963; Tator et al., 1965; Bakay, 1967 Bakay, , 1969 Bakay, , 1970 Baum, 1971; Brightman et al., 1971; Penning et al., 1971 Penning et al., , 1973 Gado et al., 1975a, b; Penning and Front, 1975) .
Penetration of pharmaceuticals into the tissue of brain tumours has been a subject of interest to a number of investigators, and a variety of directions were emphasised (Matthews and Molinaro, 1963; Tator et al., 1965; Bakay, 1967 Bakay, , 1969 Bakay, , 1970 Baum, 1971; Brightman et al., 1971; Penning et al., 1971 Penning et al., , 1973 Gado et al., 1975a, b; Penning and Front, 1975) .
Two main factors emerge as governing the passage from blood into the tissue of tumours-the vascularity of the tumour and the permeability of the blood-tissue barrier. In previous reports the role of the blood-tumour barrier in the uptake of pertechnetate was assessed (Penning et al., 1973; Penning and Front, 1975) . The role of tumour vascularity, however, could be deduced only indirectly. Radionuclide angiography and 'blood pool' studies with pertechnetate were the scintigraphic methods used for assessment of tumour vascularity. They are neither sensitive nor accurate. In radionuclide angiography, the short time interval between the frames allows only for poor statistics of the scintigrams, and only tumours with marked vascularity are clearly evident. In the blood pool studies pertechnetate, in many cases, is already penetrating into the tissue of the tumour.
ling red blood cells with 99mTC, achieving a very high tagging efficiency, creates an intravascular agent suitable for assessment of vascularity.
In this paper I compare sequential scintigraphy of brain tumours performed with 99mTc-pertechnetate for evaluation of the permeability of tumour vessels, with sequential scintigraphy performed with labelled red blood cells, and for tumour vascularity.
Methods
Forty-three patients were studied first using 99TTc-pertechnetate and 72 hours later using 99mTc-labelled red blood cells. An Anger type gamma camera and a parallel hole low energy collimator were used. Scintigrams were recorded on x-ray film using an electronic programmer and imager. The same protocol was followed in both pertechnetate and labelled red blood cells studies.
Radionuclide angiography was performed after the intravenous injection of 15 mCi of the pharmaceutical, and 16 pictures were recorded with exposure time of three seconds. A four-view study, described as the 'blood pool study', collecting 400 000 counts per scintigram, immediately followed. The final static study, using the same number of counts and views, was done after two Scintigraphic assessment of vascuilarity and blood-tissue barrier of huiman brain tumours hours. Labelling of red blood cells was performed using a Soreq kit (Soreq Nuclear Plants, Yavne, Israel) which ensures a tagging efficiency of 97%.
Strict quality control was kept in the studies with regard to the existence of free pertechnetate. Labelling was clhecked before studies, by chromatography, and in the final static scintigrams, by looking for uptake in the parotid and other salivary glands. Any such uptake was considered to indicate free pertechnetate, and the study was discarded.
Patients also underwent a neuroradiological survey consisting of all or a combination of radiocontrast angiography, pneumoencephalography, and computed tomography. In all primary brain tumours there was histological proof as to the nature of the tumour. In the metastatic tumours there was histological proof of the primary cancer. Investigations and clinical course were compatible with brain metastasis. (Gates et al., 1971; Handa, 1971; Penning et al., 1971; Ramsey and Quinn, 1972; Sheldon et al., 1975) . Some tumours are visualised early, some late, and others not at all. It is necessary to postulate some kind of barrier between the blood and the tissue of the tumour-the blood-tumour barrier (Penning et al., 1973; Gado et al., 1975a (Long, 1973 The results of this study show that the degree of penetration of the radiopharmaceutical may be independent of the amount of vascularity of the tumour at hand. In group 1 (Table, Fig. 1 (Long, 1973) , the result is significant penetration into the tumour, even when the barrier itself may not be highly permeable. Brain tumours have blood vessels that differ anatomically from normal vessels of the brain in that they have open endothelial cell junctions, gaps between endothelial cells, and fenestrations in capillary endothelial membranes (Long, 1970 (Long, , 1973 Tani et al., 1974) . These are the anatomical paths by which pharmaceuticals enter the extracellular space of tumours (Long, 1973; Gado et al., 1975a, b; Penning and Front, 1975 
Results

